Posted by Michael Wonder on 29 Sep 2021
Nonagen Bioscience granted FDA breakthrough device designation
28 September 2021 - Nonagen Bioscience today announced Oncuria, their non-invasive bladder cancer test capable of predicting response to therapy, has been granted U.S. FDA breakthrough device designation.
Oncuria, a multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.
